Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240591 | 0.88 | NPC1 (0.54) | NPC1RAB9AHSD17B3L3MBTL1CYP2J2 | |
| SCHEMBL2918005 | 0.88 | HDAC1 (0.46) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL2925517 | 0.86 | NPC1 (0.45) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL548578 | 0.84 | HSD17B3 (0.62) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL2763202 | 0.83 | NPC1 (0.42) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL1502488 | 0.83 | NPC1 (0.42) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL13525526 | 0.83 | NPC1 (0.42) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL3673275 | 0.83 | NPC1 (0.42) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL10471481 | 0.83 | NPC1 (0.53) | NPC1RAB9AHSD17B3L3MBTL1CYP2J2 | |
| SCHEMBL548940 | 0.83 | HSD17B3 (0.64) | HSD17B3L3MBTL1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269033-B2 | Process for carbonylating phenylalkyl derivatives by means of carbon monoxide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-1776330-B1 | METHOD FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20100069661-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20070161814-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| EP-1776330-A2 | METHOD FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | Sanofi-Aventis Deutschland GmbH (DE) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006002762-A2 | METHOD FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161814-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | CBR3, CBR1, CYP2E1 | NPC1 811/4885RAB9A 2736/4885HSD17B3 1283/4885 |
| US-20100069661-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | CBR3, CBR1, CYP2E1 | NPC1 811/4885RAB9A 2736/4885HSD17B3 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.